Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 5/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.53 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PPP5C | P53041 | 2/20 | 0.39 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14123972 | 1.00 | HTT (0.58) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL3832732 | 0.95 | DPP4 (0.57) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL3331935 | 0.95 | DPP4 (0.57) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL3331942 | 0.95 | DPP4 (0.57) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL24322604 | 0.90 | LMNA (0.51) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL18390884 | 0.90 | LMNA (0.51) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL3332858 | 0.88 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3332865 | 0.88 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16134880 | 0.86 | HTT (0.50) | HTTLMNADPP4DPP8DPP9 | |
| SCHEMBL21552116 | 0.86 | DPP4 (0.66) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1399436-A2 | OXYTOCIN AGONISTS | Ferring BV (NL) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003000692-A2 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | HTT 2958/4885LMNA 3333/4885DPP4 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.